NZ718607A - Synthetic route to 2’-deoxy-2’,2’-difluorotetrahydrouridines - Google Patents

Synthetic route to 2’-deoxy-2’,2’-difluorotetrahydrouridines

Info

Publication number
NZ718607A
NZ718607A NZ71860714A NZ71860714A NZ718607A NZ 718607 A NZ718607 A NZ 718607A NZ 71860714 A NZ71860714 A NZ 71860714A NZ 71860714 A NZ71860714 A NZ 71860714A NZ 718607 A NZ718607 A NZ 718607A
Authority
NZ
New Zealand
Prior art keywords
difluorotetrahydrouridines
deoxy
synthetic route
compound
catalyst
Prior art date
Application number
NZ71860714A
Inventor
Hyeong-Wook Choi
Steven Mathieu
Frank Fang
Bryan Matthew Lewis
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Publication of NZ718607A publication Critical patent/NZ718607A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06Pyrimidine radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J31/00Catalysts comprising hydrides, coordination complexes or organic compounds
    • B01J31/02Catalysts comprising hydrides, coordination complexes or organic compounds containing organic compounds or metal hydrides
    • B01J31/0201Oxygen-containing compounds
    • B01J31/0209Esters of carboxylic or carbonic acids
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J31/00Catalysts comprising hydrides, coordination complexes or organic compounds
    • B01J31/02Catalysts comprising hydrides, coordination complexes or organic compounds containing organic compounds or metal hydrides
    • B01J31/0234Nitrogen-, phosphorus-, arsenic- or antimony-containing compounds
    • B01J31/0235Nitrogen containing compounds
    • B01J31/0237Amines
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J31/00Catalysts comprising hydrides, coordination complexes or organic compounds
    • B01J31/02Catalysts comprising hydrides, coordination complexes or organic compounds containing organic compounds or metal hydrides
    • B01J31/0234Nitrogen-, phosphorus-, arsenic- or antimony-containing compounds
    • B01J31/0235Nitrogen containing compounds
    • B01J31/0244Nitrogen containing compounds with nitrogen contained as ring member in aromatic compounds or moieties, e.g. pyridine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B57/00Separation of optically-active compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00Processes for the preparation of sugar derivatives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00Processes for the preparation of sugar derivatives
    • C07H1/06Separation; Purification
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07Optical isomers
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/02Heterocyclic radicals containing only nitrogen as ring hetero atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Materials Engineering (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)

Abstract

The present invention relates to a method of producing compound 1, or a salt thereof; comprising precipitating or crystallizing compound 1 from a solution of compound 2, in the presence of a catalyst, wherein the catalyst is 1,8-diazabicyclo(5.4.0)undec-7-ene (DBU), acetic acid, trifluoroacetic acid, diisopropylethylamine, or ammonium hydroxide.
NZ71860714A 2013-10-29 2014-10-29 Synthetic route to 2’-deoxy-2’,2’-difluorotetrahydrouridines NZ718607A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361896703P 2013-10-29 2013-10-29
PCT/US2014/062874 WO2015066162A1 (en) 2013-10-29 2014-10-29 Synthetic route to 2'-deoxy-2',2'-difluorotetrahydrouridines

Publications (1)

Publication Number Publication Date
NZ718607A true NZ718607A (en) 2019-10-25

Family

ID=51982743

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ71860714A NZ718607A (en) 2013-10-29 2014-10-29 Synthetic route to 2’-deoxy-2’,2’-difluorotetrahydrouridines

Country Status (20)

Country Link
US (3) US9834576B2 (en)
EP (1) EP3063164B1 (en)
JP (1) JP6427567B2 (en)
KR (1) KR102272773B1 (en)
CN (1) CN105683209B (en)
AU (1) AU2014342402B2 (en)
BR (1) BR112016008855B1 (en)
CA (1) CA2926734C (en)
ES (1) ES2712877T3 (en)
HK (1) HK1223627A1 (en)
IL (1) IL244849B (en)
MX (1) MX363205B (en)
MY (1) MY176465A (en)
NZ (1) NZ718607A (en)
PH (1) PH12016500683A1 (en)
RU (1) RU2681939C2 (en)
SA (1) SA516371019B1 (en)
SG (1) SG11201602614XA (en)
WO (1) WO2015066162A1 (en)
ZA (1) ZA201602315B (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105683209B (en) 2013-10-29 2019-03-08 大塚制药株式会社 2 '-deoxidations -2 ', the route of synthesis of 2 '-difluoro tetrahydrouridines
US11224610B2 (en) 2018-09-19 2022-01-18 Otsuka Pharmaceutical Co., Ltd. Low dose combination CDA substrate drug/cedazuridine with extended administration
JP2022552817A (en) * 2019-10-08 2022-12-20 大塚製薬株式会社 High-purity 2'-deoxy-2',2'-difluorotetrahydrouridine and method for producing the same
CN113402573B (en) * 2020-07-31 2023-06-20 集美大学 Tannin compound and extraction method and application thereof
US20240279266A1 (en) * 2021-05-29 2024-08-22 Msn Laboratories Private Limited, R&D Center An improved process for the preparation of (4r)-1-[(2r,4r,5r)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl) oxolan-2-yl]-4-hydroxy-1,3-diazinan-2one and its intermediate compounds
TWI821074B (en) * 2021-12-25 2023-11-01 台灣神隆股份有限公司 Process for preparing cedazuridine
US20230271996A1 (en) * 2021-12-25 2023-08-31 Scinopharm Taiwan, Ltd. Process for preparing cedazuridine

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4526988A (en) 1983-03-10 1985-07-02 Eli Lilly And Company Difluoro antivirals and intermediate therefor
US5223608A (en) 1987-08-28 1993-06-29 Eli Lilly And Company Process for and intermediates of 2',2'-difluoronucleosides
US4965374A (en) 1987-08-28 1990-10-23 Eli Lilly And Company Process for and intermediates of 2',2'-difluoronucleosides
FR2682112B1 (en) 1991-10-08 1993-12-10 Commissariat A Energie Atomique PROCESS FOR THE SYNTHESIS OF RIBONUCLEIC ACID (RNA) USING A NOVEL DEPROTECTION REAGENT.
US5371210A (en) 1992-06-22 1994-12-06 Eli Lilly And Company Stereoselective fusion glycosylation process for preparing 2'-deoxy-2',2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides
US5521294A (en) 1995-01-18 1996-05-28 Eli Lilly And Company 2,2-difluoro-3-carbamoyl ribose sulfonate compounds and process for the preparation of beta nucleosides
US6001994A (en) 1995-12-13 1999-12-14 Eli Lilly And Company Process for making gemcitabine hydrochloride
US6136791A (en) 1995-12-22 2000-10-24 East Carolina University Agent and method for treating disorders associated with cytidine deaminase or deoxycytidine deaminase overexpression
US5760208A (en) 1996-08-14 1998-06-02 The Board Of Governors For Higher Education, State Of Rhode Island And Providence Plantations Process to prepare pyrimidine nucleosides
DE60144573D1 (en) 2000-11-29 2011-06-16 Mitsui Chemicals Inc Processes and intermediates in the synthesis of L-thymidine
FI112640B (en) 2000-12-22 2003-12-31 Kone Corp Elevator safety device
EA014909B1 (en) * 2006-06-21 2011-02-28 Эли Лилли Энд Компани Crystalline forms of gemcitabine amide prodrug, compositions based thereon and use thereof
JO2778B1 (en) * 2007-10-16 2014-03-15 ايساي انك Certain Compounds, Compositions and Methods
CN105683209B (en) 2013-10-29 2019-03-08 大塚制药株式会社 2 '-deoxidations -2 ', the route of synthesis of 2 '-difluoro tetrahydrouridines

Also Published As

Publication number Publication date
IL244849B (en) 2019-10-31
SG11201602614XA (en) 2016-05-30
PH12016500683B1 (en) 2016-05-30
KR102272773B1 (en) 2021-07-02
AU2014342402B2 (en) 2018-11-01
EP3063164B1 (en) 2018-12-05
HK1223627A1 (en) 2017-08-04
SA516371019B1 (en) 2018-01-23
US11028119B2 (en) 2021-06-08
JP6427567B2 (en) 2018-11-21
US10526362B2 (en) 2020-01-07
JP2017500281A (en) 2017-01-05
US20200123189A1 (en) 2020-04-23
BR112016008855A2 (en) 2017-08-01
CN105683209B (en) 2019-03-08
CN105683209A (en) 2016-06-15
WO2015066162A1 (en) 2015-05-07
US20160237107A1 (en) 2016-08-18
RU2681939C2 (en) 2019-03-14
IL244849A0 (en) 2016-05-31
EP3063164A1 (en) 2016-09-07
US20180072768A1 (en) 2018-03-15
MY176465A (en) 2020-08-11
MX363205B (en) 2019-03-13
BR112016008855B1 (en) 2023-01-17
CA2926734C (en) 2022-03-15
PH12016500683A1 (en) 2016-05-30
AU2014342402A1 (en) 2016-04-21
US9834576B2 (en) 2017-12-05
RU2016115523A (en) 2017-12-04
MX2016005596A (en) 2016-12-09
CA2926734A1 (en) 2015-05-07
ES2712877T3 (en) 2019-05-16
KR20160083021A (en) 2016-07-11
ZA201602315B (en) 2019-07-31
RU2016115523A3 (en) 2018-06-05

Similar Documents

Publication Publication Date Title
NZ718607A (en) Synthetic route to 2’-deoxy-2’,2’-difluorotetrahydrouridines
EA201390235A1 (en) METHOD OF OBTAINING CARBONILE COMPOUNDS
WO2013014665A8 (en) Intermediate compounds and process for the preparation of lurasidone and salts thereof
MX2013000009A (en) Process for the preparation of the l-arginine salt of perindopril.
MX2015009617A (en) Crystalline forms of {[1-cyano-5-(4-chlorophenoxy)-4-hydroxy-isoq uinoline-3-carbonyl]-amino}-acetic acid.
FR2972452B1 (en) PROCESS FOR THE PREPARATION OF DIFLUOROACETONITRILE AND ITS DERIVATIVES
WO2016142819A3 (en) Novel process for the preparation of ranolazine
BR112019001447A2 (en) Production method for pyrazol amide compound
WO2012140490A3 (en) Processes for preparing pitavastatin calcium
BR112016006865A2 (en) substituted berberines and their syntheses
MY194792A (en) Method for producing optically active 2-(2-fluorobiphenyl-4-yl) propanoic acid
ECSP13012365A (en) CRYSTAL FORM DELTA OF THE ARGININE SALT OF PERINDOPRILE, ITS PREPARATION PROCEDURE,
MX2012001722A (en) New method for synthesising ivabradine and its added salts with a pharmaceutically acceptable acid.
MY191759A (en) Processes for the preparation of pyrimidinylcyclopentane compounds
TN2014000329A1 (en) Method for preparing compound by novel michael addition reaction using water or various acids as additive
MY182164A (en) Process for producing acetic acid by introducing a lithium compound
WO2014173917A8 (en) Synthesis of bace inhibitors
IN2013MU00916A (en)
UA111329C2 (en) Process for the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid
WO2016202808A3 (en) NEW SYNTHESIS OF TAPENTADOL-HCl INTERMEDIATES
WO2015084693A3 (en) New process for preparing loratadine from a ketone intermediate
PH12018501046A1 (en) Crystals of monovalent cation salt of 3-hydroxyisovaleric acid, and method for producing said crystals
WO2015050199A3 (en) Novel compound, production method therefor, and application therefor
PH12015501840A1 (en) Production method of pyridazinone compounds
WO2015001565A3 (en) "an improved process for the preparation of 3-aryloxy-3- phenylpropylamine and salt thereof"

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 29 OCT 2021 BY COMPUTER PACKAGES INC

Effective date: 20201001

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 29 OCT 2022 BY CPA GLOBAL

Effective date: 20210916

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 29 OCT 2023 BY CPA GLOBAL

Effective date: 20220915

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 29 OCT 2024 BY CPA GLOBAL

Effective date: 20230914